Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS ANNOUNCES ENTRY INTO LOAN AGREEMENTS

Onco-Innovations Ltd. has entered into three loan agreements with certain lenders providing for loans to the company in the aggregate principal amount of up to $280,000.

Two of the loans are from arm's-length shareholders of the company, pursuant to which the company may make demand for the principal amounts of up to $20,000 and $60,000, respectively. The shareholder loans bear interest at a rate of 15 per cent per annum, calculated monthly, and are repayable on demand. The shareholder loans may be prepaid in whole or in part at any time without premium or penalty, with any prepayment to be credited first to accrued but unpaid interest and then to principal.

The third loan is from Dr. Islam Mohamed, the chief medical officer of the company, in the amount of $200,000. The other loan bears interest at a rate of 1 per cent per month, calculated monthly, and is repayable in two equal tranches of $100,000, with the first tranche due on or before Sept. 13, 2026, and the second tranche due on or before Nov. 13, 2026, subject to earlier repayment on demand or acceleration upon an event of default. If any amount is not repaid when due, an additional 2 per cent per month will accrue on overdue amounts, resulting in an aggregate default rate of 3 per cent per month on overdue amounts. The other loan may be prepaid in whole or in part upon written notice, subject to a prepayment fee equal to 2 per cent of the amount prepaid, plus all interest that would otherwise have accrued and been payable through the applicable maturity date.

The company expects to use the proceeds of the shareholder loans for general working capital purposes. The proceeds of the other loan may only be used for specific third party research and development vendors identified in the other loan agreement.

As Dr. Mohamed is the chief medical officer of the company, he is a related party of the company. Accordingly, the other loan constitutes a related-party transaction within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). The company will rely on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 set out in sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, on the basis that the fair market value of the other loan does not exceed 25 per cent of the company's market capitalization, as determined in accordance with MI 61-101.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.